The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Presence of increased fat tissue (epicardial fat) around the heart significantly contributes to greater damage of heart ...

Living with chronic hepatitis? Simple lifestyle changes can protect your liver, support treatment, and help maintain a ...

Gynecomastia and chest fat may look similar but need different solutions. Learn how to identify the signs, avoid misdiagnosis ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body ...

Hello, and welcome to Wave Life Sciences Positive Interim Clinical Data from INLIGHT Trial of WVE-007 and Obesity call. [Operator Instructions]. Also, as a reminder, this conference is being recorded ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

The clinical-stage biotechnology company announced that a single 240 mg dose of WVE-007 demonstrated improved body composition after three months, including a 9.4% reduction in visceral fat, a 4.5% ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the ...

Although BMI is what most doctors use to track weight loss, that doesn’t necessarily mean it’s the most accurate.

A BMI of 40 kg/m 2 or higher is considered morbidly obese. Morbid obesity can increase the risk of serious health problems ...